Prodrugs of NAAG Peptidase Inhibitors for the Treatment of Schizophrenia

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$620,426.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43MH083350-01
Award Id:
89359
Agency Tracking Number:
MH083350
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
765 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
004812744
Principal Investigator:
JIA ZHOU
(914) 593-8378
JIA.ZHOU@PSYCHOGENICS.COM
Business Contact:
() -
bill.fasnacht@psychogenics.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Schizophrenia is a chronic, severe, and disabling brain disease. Nearly 1 percent of the population develops schizophrenia during their lifetime - more than 2 million Americans suffer from this disease in a given year. The schizophrenia world market generated total revenues of nearly 12 billion in 2004 and is still growing steadily. Atypical antipsychotic drugs, such as clozapine, risperidone, and olanzapine are widely used to treat schizophrenia but are not fully effec tive in moderating the positive, negative and cognitive symptoms that different patients present. These drugs act primarily via antagonism of dopamine and serotonin receptors. However, a substantial literature supports the involvement of glutamatergic circ uits in mediating the symptoms of schizophrenia in humans and animal models of this disorder. As a result, glutamate receptor ligands are under active analysis as potential alternative and adjuvant therapy for the treatment of this disorder. Among these ar e activators of the glycine site on the NMDA receptor and group II metabotropic glutamate receptor (mGluR) agonists. N-Acetylaspartylglutamate (NAAG) is the third most prevalent transmitter in the mammalian nervous system and a group II mGluR (mGluR3gtgtmG luR2) selective agonist. It is inactivated by extracellular peptidases (GCPII and III) to N-acetylaspartate (NAA) and glutamate (Glu) following the release of the peptide into the synaptic space. Inhibition of GCPII and III increases NAAG levels with the c onsequent activation of presynaptic group II mGluRs. Group II mGluR activation inhibits the release of glutamate and reduces the schizophrenia-like behavioral symptoms elicited by phencyclidine (PCP). Our research team demonstrated that NAAG peptidase inhi bition and subsequent group II mGluR activation by NAAG also reduces these behaviors and thus potentially represents a new therapeutic approach to schizophrenia and acute PCP intoxication. After extensive SAR studies, our research team has identified a num ber of urea-based compounds, including ZJ 43, ZJ 11 and ZJ 17, as NAAG peptidase inhibitors with nanomolar potency. Systemic administration of the NAAG peptidase inhibitor ZJ 43 reduces PCP-induced behaviors in a rat model of schizophrenia, and this action of ZJ 43 is blocked by the group II mGluR antagonist LY341495. However, there exists an important concern that these compounds are too polar to readily penetrate the blood-brain barrier (BBB) and to advance to human clinical studies. The development of pr odrugs will provide the means for precise dose delivery to the brain to improve their efficacy as well as the use of lower dose ranges that obviate the problem of unwanted systemic side effects. The long-term goal of this research project is to develop the se NAAG peptidase inhibitors as novel therapeutics or adjuvant therapies for schizophrenia. In order to accelerate the development and application of these compounds for human clinical trials, the immediate goal of this research proposal is to develop nove l prodrugs to improve the BBB penetration capabilities of our candidate NAAG peptidase inhibitors to improve their efficacy. It is noteworthy that our very recent preliminary data have demonstrated that one mono-ester prodrug of ZJ 43 is about 7-fold more active than the parent drug ZJ 43 in our PCP-induced behavioral model of schizophrenia. These findings encouraged us to pursue further studies on the design, synthesis and pharmacological investigation of prodrugs of our NAAG peptidase inhibitors. Through funding from this SBIR Phase I grant, we intend to bring our discovery of the efficacy of NAAG peptidase inhibitors in animal models of schizophrenia to a higher level of preclinical development and ultimately to foster the translation of this concept into clinical trials. Specific Aim 1: Synthesis of compounds: Rational design and synthesis of new prodrug forms of lead NAAG peptidase inhibitors. Based upon the

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government